Insider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Major Shareholder Sells 55,000 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) major shareholder Rock Ventures Iii L.P. Third sold 55,000 shares of the company’s stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $9.06, for a total transaction of $498,300.00. Following the completion of the sale, the insider now owns 5,273,933 shares of the company’s stock, valued at approximately $47,781,832.98. The sale was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Rock Ventures Iii L.P. Third also recently made the following trade(s):

• On Friday, January 20th, Rock Ventures Iii L.P. Third sold 100,000 shares of Voyager Therapeutics stock. The shares were sold at an average price of $9.15, for a total transaction of $915,000.00.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock traded up $0.32 during trading hours on Tuesday, hitting $9.48. The company had a trading volume of 372,177 shares, compared to its average volume of 755,505. The firm has a market capitalization of $365.99 million, a P/E ratio of -20.61 and a beta of 0.92. The firm’s fifty day moving average is $6.64 and its 200-day moving average is $6.31. Voyager Therapeutics, Inc. has a fifty-two week low of $2.74 and a fifty-two week high of $10.81.

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.64. Voyager Therapeutics had a negative net margin of 24.21% and a negative return on equity of 21.97%. The firm had revenue of $41.09 million for the quarter, compared to analyst estimates of $21.25 million. Analysts anticipate that Voyager Therapeutics, Inc. will post -1.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VYGR. Armistice Capital LLC increased its stake in shares of Voyager Therapeutics by 32.4% during the 3rd quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock worth $20,104,000 after purchasing an additional 832,000 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Voyager Therapeutics by 1,735.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 827,950 shares of the company’s stock worth $4,893,000 after purchasing an additional 782,850 shares during the last quarter. Millennium Management LLC increased its stake in shares of Voyager Therapeutics by 291.0% during the 2nd quarter. Millennium Management LLC now owns 828,796 shares of the company’s stock worth $4,898,000 after purchasing an additional 616,814 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth $1,713,000. Finally, Marshall Wace LLP acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth $1,123,000. Institutional investors and hedge funds own 59.58% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 14th.

Voyager Therapeutics Company Profile

(Get Rating)

Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.